Alzheimer's Disease + Vascular Dementia + Acetyl-L-Carnitine

_Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia].

AbstractEfficacy,
safety and tolerability of acetyl-L-carnitine (ALC) were studied during
the double-blind placebo-controlled 12-week trial in patients with mild
(initial) dementia caused by the Alzheimer's disease (AD) and vascular
dementia (VD). ALC was administered in doses from 2250 to 3000 mg per
day. Patient's state was assessed with some scales (MMSE, CGI etc) and a
battery of neuropsychological tests. The treatment effect of ALC was
2,8 times higher than in placebo-treated patients. The clinical
improvement by CGI scores was significantly better in AD patients
compared to VD and did not depend on the severity of baseline cognitive
deficit. The drug was well-tolerated. Carnicetine can be recommended in
the abovementioned doses for treatment of early stages of AD and VD.